Covered recipient · General Payments record
BRITTANY A WYGER
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$1,500.47
- Reported across 84 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $406.62 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Amgen Inc. | $121.80 | 1 |
| ABBVIE INC. | $69.11 | 3 |
| Novo Nordisk AS | $49.13 | 3 |
| PFIZER INC. | $39.79 | 2 |
| Lilly USA, LLC | $38.68 | 2 |
| Takeda Pharmaceuticals U.S.A., Inc. | $35.05 | 2 |
| Currax Pharmaceuticals LLC | $29.67 | 2 |
| Axsome Therapeutics, Inc. | $23.39 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $24.75 | 02/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106365716 | CMS |
| ABBVIE INC. | $27.98 | 04/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106365718 | CMS |
| ABBVIE INC. | $16.38 | 06/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106365720 | CMS |
| Amgen Inc. | $121.80 | 04/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111743106 | CMS |
| Axsome Therapeutics, Inc. | $23.39 | 04/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148269082 | CMS |
| Currax Pharmaceuticals LLC | $16.32 | 09/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089509570 | CMS |
| Currax Pharmaceuticals LLC | $13.35 | 10/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089509572 | CMS |
| Lilly USA, LLC | $23.67 | 05/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136080107 | CMS |
| Lilly USA, LLC | $15.01 | 09/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1136080414 | CMS |
| Novo Nordisk Inc | $17.39 | 05/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096648358 | CMS |
| Novo Nordisk Inc | $18.61 | 08/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096926586 | CMS |
| Novo Nordisk Inc | $13.13 | 09/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097678565 | CMS |
| PFIZER INC. | $22.53 | 02/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131800021 | CMS |
| PFIZER INC. | $17.26 | 06/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131797438 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $18.91 | 03/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137700126 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $16.14 | 12/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137700128 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.